ClinVar Miner

Submissions for variant NM_001009944.3(PKD1):c.2039A>T (p.Tyr680Phe) (rs370141157)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
PreventionGenetics,PreventionGenetics RCV000242445 SCV000305705 likely benign not specified criteria provided, single submitter clinical testing
Athena Diagnostics Inc RCV000242445 SCV001475359 benign not specified 2020-09-01 criteria provided, single submitter clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001292234 SCV001481065 benign Polycystic kidney disease no assertion criteria provided clinical testing The PKD1 p.Tyr680Phe variant was identified in 2 of 98 proband chromosomes (frequency: 0.020) from individuals or families with ADPKD in the Chinese population. Family analysis showed that the variant does not co-segregate with ADPKD and was classified as a probable polymorphism (Liu 2015, Xiao-Ping 2012). The variant was also identified in dbSNP (ID: rs370141157) as “with likely benign allele”; in the Clinvitae and Clinvar databases (as likely benign by Prevention Genetics) and in ADPKD Mutation Database 2x as likely neutral. The variant was further identified in the 1000 Genomes Project in 16 of 5000 chromosomes (frequency: 0.0032); the genome Aggregation Database (February 27, 2017) in 217 of 237604 chromosomes (freq. 0.001); and in the Exome Aggregation Consortium database (August 8th 2016) in 73 of 33700 chromosomes (freq. 0.002) in the following populations: East Asian in 69 of 1894 chromosomes (freq. 0.036), South Asian in 2 of 8840 chromosomes (freq. 0.0002), European (Non-Finnish) in 1of 17664 chromosomes (freq. 0.0001), other in 1 of 280 chromosomes and not seen in the African and Finnish populations increasing the likelihood this could be a low frequency benign variant. In addition we cannot be certain that data from control databases is specific to PKD1 and not from one of the six PKD1 pseudogenes. The variant was not identified in GeneInsight COGR, MutDB, PKD1-LOVD and PKD1-LOVD 3.0 databases and the NHLBI GO Exome Sequencing Project. In addition the variant was identified with a co-occurring pathogenic PKD2 variant (p.Arg803X), increasing the likelihood that the p.Tyr680Phe variant does not have clinical significance. The p.Tyr680 residue is not conserved in mammals and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information, this variant meets our laboratory criteria to be classified as benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.